Vedolizumab-5056: Clinical Effectiveness of Vedolizumab Used in Frames of Drug Program for Crohn’s Disease Treatment in Poland – Prospective, Observational Study Considering Fatigue and Other Patient-reported-outcomes (PROs) (POLONEZ II)

28/01/2020
25/06/2024
EU PAS number:
EUPAS32716
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Vedolizumab-5056-clinical-study-protocol-redact.pdf

English (11.61 MB - PDF) View document
Study results
Study report
Study report

Vedolizumab-5056-clinical-study-report-redact.pdf

English (1.29 MB - PDF) View document
Other information